Search Intelligence

“Shelling out half a billion upfront for the mere option to pay $7 billion later shows exactly how desperate legacy pharma is to capture the post-vaccine mRNA market.”

“Pharma's favorite strategy of buying their way out of a patent cliff hits a wall when the acquired pipeline repeatedly faceplants in Phase 3.”

“Billions spent hyping a biological mechanism only to watch the clinical trial completely collapse on first contact with reality.”